Rocket Pharmaceuticals Inc’s recent filing unveils that its insider Schwartz Jonathan David unloaded Company’s shares for reported $69109.0 on Feb 25 ’25. In the deal valued at $10.58 per share,6,532 shares were sold. As a result of this transaction, Schwartz Jonathan David now holds 237,638 shares worth roughly $2.06 million.
Then, Schwartz Jonathan David sold 2,754 shares, generating $64,306 in total proceeds. Upon selling the shares at $23.35, the insider now owns 169,659 shares.
Before that, Schwartz Jonathan David sold 2,710 shares. Rocket Pharmaceuticals Inc shares valued at $50,135 were divested by the insider at a price of $18.50 per share. As a result of the transaction, Schwartz Jonathan David now holds 166,949 shares, worth roughly $1.45 million.
Wedbush initiated its Rocket Pharmaceuticals Inc [RCKT] rating to an Outperform in a research note published on December 30, 2024; the price target was $32. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Scotiabank began covering RCKT with “Sector outperform” recommendation on October 16, 2024. Goldman started covering the stock on April 02, 2024. It rated RCKT as “a Neutral”.
Price Performance Review of RCKT
On Tuesday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -1.48% to $8.66. Over the last five days, the stock has lost -7.48%. Rocket Pharmaceuticals Inc shares have fallen nearly -31.11% since the year began. Nevertheless, the stocks have fallen -70.44% over the past one year. While a 52-week high of $30.94 was reached on 01/02/25, a 52-week low of $8.78 was recorded on 03/04/25. SMA at 50 days reached $10.80, while 200 days put it at $16.98.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 8.33, which if violated will result in even more drops to 8.00. On the upside, there is a resistance level at 8.91. A further resistance level may holdings at 9.15. The Relative Strength Index (RSI) on the 14-day chart is 29.47, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.94, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.66%. Stochastics %K at 12.76% indicates the stock is a buying.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
